Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea · Delayed Price · Currency is KRW 5,950.00
+130.00 (2.23%)
At close: Aug 24, 2026
Sinil Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 82,183 | 80,564 | 89,440 | 89,135 | 80,007 | 61,754 |
Other Revenue | -0 | -0 | -0 | - | -0 | - |
| 82,183 | 80,564 | 89,440 | 89,135 | 80,007 | 61,754 | |
Revenue Growth | -4.35% | -9.93% | 0.34% | 11.41% | 29.56% | 0.52% |
Cost of Revenue | 46,985 | 47,127 | 48,774 | 51,565 | 44,362 | 37,313 |
Gross Profit | 35,198 | 33,437 | 40,666 | 37,570 | 35,645 | 24,441 |
Selling, General & Admin | 24,677 | 22,636 | 21,238 | 19,491 | 17,623 | 15,574 |
Research & Development | 3,133 | 2,694 | 2,802 | 2,979 | 3,264 | 194.52 |
Other Operating Expenses | 334.34 | 422.17 | 347.33 | 355.82 | 378.68 | 374.75 |
Operating Expenses | 28,450 | 26,052 | 25,445 | 23,579 | 21,989 | 16,459 |
Operating Income | 6,747 | 7,386 | 15,222 | 13,991 | 13,656 | 7,982 |
Interest Expense | -17.71 | -19.71 | -26.97 | -26.13 | -6.05 | -9.72 |
Interest & Investment Income | 1,118 | 1,149 | 1,074 | 849.37 | 352.84 | 184.48 |
Currency Exchange Gain (Loss) | 54.73 | -21.61 | 43.68 | -59.59 | 90.91 | 26.14 |
Other Non Operating Income (Expenses) | 62.81 | 19.04 | 217.24 | 1,379 | 899.91 | 14.64 |
EBT Excluding Unusual Items | 7,965 | 8,512 | 16,530 | 16,134 | 14,994 | 8,197 |
Gain (Loss) on Sale of Investments | 6.97 | 1.34 | -26.81 | -532.61 | -478.44 | 115.48 |
Gain (Loss) on Sale of Assets | -322.59 | -24.33 | 3.72 | -641.55 | 221.3 | 14 |
Asset Writedown | 108.28 | 108.28 | 31 | -7 | -92.08 | 14.5 |
Pretax Income | 7,757 | 8,597 | 16,538 | 14,953 | 14,645 | 8,341 |
Income Tax Expense | 805.86 | 1,067 | 2,237 | 1,312 | 2,488 | 1,663 |
Net Income | 6,951 | 7,531 | 14,301 | 13,641 | 12,157 | 6,679 |
Net Income to Common | 6,951 | 7,531 | 14,301 | 13,641 | 12,157 | 6,679 |
Net Income Growth | -45.06% | -47.34% | 4.83% | 12.21% | 82.02% | -11.47% |
Shares Outstanding (Basic) | 12 | 12 | 12 | 12 | 11 | 11 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 11 | 11 |
Shares Change | - | - | -0.02% | 3.94% | -1.05% | -0.11% |
EPS (Basic) | 601.36 | 651.49 | 1237.13 | 1179.82 | 1092.89 | 594.11 |
EPS (Diluted) | 601.36 | 651.49 | 1237.13 | 1179.82 | 1092.89 | 594.11 |
EPS Growth | -45.06% | -47.34% | 4.86% | 7.95% | 83.95% | -11.37% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 5,595 | 8,444 | 12,327 | 1,551 | 3,336 | 7,820 |
Free Cash Flow Per Share | 484.03 | 730.46 | 1066.39 | 134.13 | 299.94 | 695.63 |
Gross Margin | 42.83% | 41.50% | 45.47% | 42.15% | 44.55% | 39.58% |
Operating Margin | 8.21% | 9.17% | 17.02% | 15.70% | 17.07% | 12.93% |
Profit Margin | 8.46% | 9.35% | 15.99% | 15.30% | 15.20% | 10.81% |
Free Cash Flow Margin | 6.81% | 10.48% | 13.78% | 1.74% | 4.17% | 12.66% |
EBITDA | 12,834 | 13,377 | 20,828 | 19,353 | 18,088 | 12,518 |
EBITDA Margin | 15.62% | 16.60% | 23.29% | 21.71% | 22.61% | 20.27% |
D&A For EBITDA | 6,087 | 5,991 | 5,607 | 5,361 | 4,432 | 4,536 |
EBIT | 6,747 | 7,386 | 15,222 | 13,991 | 13,656 | 7,982 |
EBIT Margin | 8.21% | 9.17% | 17.02% | 15.70% | 17.07% | 12.93% |
Effective Tax Rate | 10.39% | 12.40% | 13.53% | 8.77% | 16.99% | 19.93% |
Advertising Expenses | - | 622.21 | 980.01 | 1,059 | 762.13 | 157.25 |